Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

DPH 2,110.75 -1.25 (-0.06%)
price chart
Dechra Pharmaceuticals PLC: Australian Acquisition-Apex Laboratories for A$55m
Dechra is pleased to announce that it has agreed terms to acquire the business and assets of Apex Laboratories Pty Ltd ('Apex'), a privately owned veterinary pharmaceutical company which manufactures, markets and sells branded non-proprietary ...
Dechra� Pharmaceuticals PLC Trading Update
International specialist veterinary pharmaceuticals and related products business, Dechra Pharmaceuticals PLC (Dechra or the Company) (Stock Code: Full Listing (Pharmaceuticals): DPH) issues the following unaudited Trading Update covering the half year ...
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...
Pharmaceutical giants Dechra Pharmaceuticals (LSE: DPH) and GlaxoSmithKline (LSE: GSK) took divergent paths in Monday morning business despite both releasing positive updates.
Dechra Pharmaceuticals PLC: Annual Results  PR Newswire (press release)
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
Dechra to acquire Putney, maker of generic veterinary drugs, for $200 million  dvm360
OP animal health parent leashes $200M acquisition  Kansas City Business Journal
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Dechra Pharmaceuticals PLC - 20 Years of Strategic Growth
"As we complete our 20th year since the inception of the Company, we are pleased to report that the Group has delivered another strong financial performance.
2 stocks that could make you rich  Motley Fool UK
TOP NEWS: Dechra Lifts Dividend 16% As Annual Profit Near Doubles  London South East (registration) (blog)
Does Dechra Pharmaceuticals plc's (LSE:DPH) 98.1% Earnings Growth Make It An ...
To deliver an EPS growth of 98.13% over the past year for a company of Dechra Pharmaceuticals plc (LSE:DPH)'s size—a market capitalization of GBP �2.01B— is no mean feat.
Insperity (NSP) Reaches $93.55 52-Week High; Dechra Pharmaceuticals plc (LON ...  UtahHerald.com
Outstanding Analyst Ratings For Dechra Pharmaceuticals (LON:DPH)  UK Market News
Dechra� Pharmaceuticals PLC (Dechra or the Group) : Trading Update
The Board of Dechra Pharmaceuticals PLC (LSE:DPH), issues the following unaudited Trading Update ahead of the Group's half-year financial results for the period ended 31 December 2015, which will be announced on Monday, 22 February 2016.
Share Activity Lifted for Dechra Pharmaceuticals Plc (DPH.L) in Session
Dechra Pharmaceuticals Plc (DPH.L) shares are moving today on volatility 0.17% or 3.50 from the open. The LSE listed company saw a recent bid of 2115.50 and 30871 shares have traded hands in the session.
22.35
Dechra Pharmaceuticals PLC is a holding company, which engages in the veterinary pharmaceuticals and related products business.